Amadix develops and commercializes breakthrough discoveries in cancer diagnosis with a clear commercial rationale, addressing unmet medical needs in oncology. After analytical validation and demonstration of clinical validity and utility through international multicentre studies, the products will be commercialized worldwide.
In cancer, personalized medicine uses specific information about a person’s tumor to help diagnose, make a prognosis, plan treatment or to find out how well the treatment is working. Amadix´s personalized medicine strategy aims to provide diagnostic tools that support the physician’s decisions about patient management, in order to give the right treatment to the right patient.
As of today, Amadix has a pipeline of innovative and non-invasive tests under development for screening and early diagnostic uses in colon, lung and pancreatic cancer. The company has conducted clinical studies in more than twenty hospitals for different types of cancer. All Amadix products are duly protected by patents worldwide, with patent protection in eleven territories including the US, Europe and Japan.
The most advanced product developed by Amadix is Colofast, an innovative non-invasive screening signature for colorectal cancer (CRC) and advanced adenoma diagnosis in blood designed to solve a significant health priority: the high mortality rate due to colon cancer worldwide (around half of the diagnosed patients).
Amadix team consist of industry veterans with robust expertise in the Oncology Diagnostic area. They are a top level management team with international experience in cancer diagnostics, the pharmaceutical industry, the biotechnology sector and intellectual property. Amadix also has independent board members with international profiles and many years of experience in oncology and diagnostics, who advise the management team on strategy, commercialization and business development in Europe and the US.
https://youtu.be/QxsztlVdlvk
In cancer, personalized medicine uses specific information about a person’s tumor to help diagnose, make a prognosis, plan treatment or to find out how well the treatment is working. Amadix´s personalized medicine strategy aims to provide diagnostic tools that support the physician’s decisions about patient management, in order to give the right treatment to the right patient.
As of today, Amadix has a pipeline of innovative and non-invasive tests under development for screening and early diagnostic uses in colon, lung and pancreatic cancer. The company has conducted clinical studies in more than twenty hospitals for different types of cancer. All Amadix products are duly protected by patents worldwide, with patent protection in eleven territories including the US, Europe and Japan.
The most advanced product developed by Amadix is Colofast, an innovative non-invasive screening signature for colorectal cancer (CRC) and advanced adenoma diagnosis in blood designed to solve a significant health priority: the high mortality rate due to colon cancer worldwide (around half of the diagnosed patients).
Amadix team consist of industry veterans with robust expertise in the Oncology Diagnostic area. They are a top level management team with international experience in cancer diagnostics, the pharmaceutical industry, the biotechnology sector and intellectual property. Amadix also has independent board members with international profiles and many years of experience in oncology and diagnostics, who advise the management team on strategy, commercialization and business development in Europe and the US.
https://youtu.be/QxsztlVdlvk
Location: Spain, Castile and León, Valladolid
Employees: 11-50
Founded date: 2010
Investors 1
| Date | Name | Website |
| - | Startup Fa... | sanfrancis... |
Mentions in press and media 6
| Date | Title | Description |
| 23.01.2024 | FDA Grants Breakthrough Device Designation to Amadix´s preventive screening blood test for Colorectal Cancer | PreveCol®, a blood test for oncological diagnosis, has obtained US recognition for its efficacy in detecting precancerous lesions compared to existing alternatives in the United States. Amadix becomes the first European company to announce ... |
| 19.01.2022 | Amadix, participada por Sodical, consigue una subvención de €2,5M procedentes del programa EIC Accelerator. | 19/01/2022 Nota de prensa AMADIX, PARTICIPADA POR SODICAL, CONSIGUE UNA SUBVENCIÓN DE €2,5 MILLONES PROCEDENTES DEL PROGRAMA EIC ACCELERATOR. Advanced Marker Discovery (Amadix), empresa participada por Sodical, recibirá una subvención de... |
| 27.10.2020 | El CDTI invierte junto a CRB Bio II, FCR en la startup biotecnológica Amadix | 27/10/2020 Nota de prensa EL CDTI INVIERTE JUNTO A CRB BIO II, FCR EN AMADIX, STARTUP BIOTECNOLÓGICA QUE DESARROLLA TEST INNOVADORES PARA LA DETECCIÓN TEMPRANA DE CÁNCER EN MUESTRAS DE SANGRE. El CDTI, a través de su programa Innvierte, ... |
| 28.11.2019 | Amadix, participada por CRB Inverbío e Inveready, cierra una ronda de €1,2M con The Crowd Angel | 28/11/2019 AMADIX, PARTICIPADA POR CRB INVERBÍO E INVEREADY, CIERRA UNA RONDA DE €1,2 MILLONES CON THE CROWD ANGEL. Amadix ha cerrado una ronda de €1,2 millones a través de la plataforma de financiación colectiva The Crowd Angel. La compa... |
| 10.02.2013 | Amadix Merges with Transbiomed and Raises €2M in Funding | Amadix (Advanced Marker Discovery), a Valladolid, Spain-based biotechnology company, merged with Transbiomed and raised €2m in funding. Backers included CRB Bio II, a Life Sciences fund managed by CRB Inverbío, which committed €1,5m, and th... |
| - | Amadix | “Discover more about our new breakthrough technology which allows to detect early signs of cancer in the body’s bloodstream. ¡Visit our website!” |